Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 15/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059134 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL4997375 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196092 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7561514 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL8395090 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196099 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196095 | 1.00 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL2752706 | 0.98 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7440101 | 0.98 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL2753457 | 0.98 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513302-B2 | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-20 | — | — | US | claimed |
| US-20110269831-A1 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-03 | — | — | US | claimed |
| US-20100317733-A1 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-16 | — | — | US | claimed |
| US-20060148744-A1 | Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-07-06 | — | — | US | claimed |
| US-20050222252-A1 | Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-06 | — | — | US | claimed |
| EP-1575489-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2003061597-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-31 | — | — | WO | claimed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | disclosed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | disclosed |
| US-20030119900-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-06-26 | — | — | US | disclosed |
| US-20030113824-A1 | Dihydroxy unsaturated fatty acid levels as diagnostic markers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-19 | — | — | US | disclosed |
| US-6531506-B1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-03-11 | — | — | US | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269831-A1 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885KDM4E 1167/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX1 25/4885EPHX2 51/4885KDM4E 2028/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885EPHX2 2/4885KDM4E 2385/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | EPHX1 25/4885EPHX2 51/4885KDM4E 2028/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX1 8/4885EPHX2 10/4885KDM4E 2486/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | EPHX1 3353/4885EPHX2 3967/4885KDM4E 4309/4885 |
| US-20030119900-A1 | Inhibitors of epoxide hydrolases for the treatment of hypertension | EPHX1, NCEH1, EPHX2 | EPHX1 1/4885EPHX2 3/4885KDM4E 775/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX1 116/4885EPHX2 127/4885KDM4E 3408/4885 |
| US-20100317733-A1 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | EPHX1, EPHX2, LTA4H | EPHX1 1/4885EPHX2 2/4885KDM4E 2679/4885 |
| US-20030113824-A1 | Dihydroxy unsaturated fatty acid levels as diagnostic markers | ALOX12, ALOX15, ALOX5 | EPHX1 15/4885EPHX2 9/4885KDM4E 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.